Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Sensus Healthcare, Inc. has a consensus rating of "Hold" from five research firms, with two analysts recommending a sell and three giving a buy recommendation.
• The average one-year price target for Sensus Healthcare is $8.00, following recent downgrades from several analysts.
• The company's stock is currently trading at $3.43, experiencing a rise of 3.6%, with a market capitalization of $56.39 million.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) has received an average rating of "Hold" from the five research firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $8.00.

Several analysts have issued reports on the company. Wall Street Zen cut Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd. HC Wainwright dropped their target price on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sensus Healthcare in a research report on Saturday, September 27th. Lake Street Capital dropped their target price on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Zacks Research cut Sensus Healthcare from a "hold" rating to a "strong sell" rating in a research report on Tuesday, September 23rd.

Sensus Healthcare Stock Up 3.6%

NASDAQ:SRTS traded up $0.12 during midday trading on Friday, hitting $3.43. The stock had a trading volume of 113,415 shares, compared to its average volume of 173,418. Sensus Healthcare has a one year low of $3.03 and a one year high of $9.33. The company has a market capitalization of $56.39 million, a price-to-earnings ratio of -57.17 and a beta of 1.38. The stock has a 50-day moving average of $3.67 and a 200 day moving average of $4.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.07). The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. On average, sell-side analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Institutional Trading of Sensus Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in SRTS. Millennium Management LLC lifted its holdings in shares of Sensus Healthcare by 256.6% during the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock valued at $590,000 after purchasing an additional 61,403 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Sensus Healthcare during the 1st quarter valued at $71,000. Chapin Davis Inc. lifted its holdings in shares of Sensus Healthcare by 50.0% during the 1st quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock valued at $71,000 after purchasing an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sensus Healthcare by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after purchasing an additional 5,289 shares during the last quarter. Finally, Larson Financial Group LLC purchased a new position in Sensus Healthcare in the 1st quarter worth $26,000. Hedge funds and other institutional investors own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.